Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Julia Castro Pichel

Esther Pilar Fernandez Velando

Raquel Fernandez Menendez

Silvia Gonzalez Del Valle

Lluis Ballell Pages

Neil David Pearson

Alan Joseph Hennessy

Graham Elgin Jones

David Thomas Davies

Steven Dabbs

Timothy James Miles

Israil Pendrak

Robert A Daines

Gerald Brooks

Jose Maria Fiandor Roman

Robert H Bates

David Barros Aguirre

Jorge Esquivias Provencio

Alfonso Mendoza Losana

Kevin Pethe

David Barros

Lihua Zhang

Lihua(lily) Zhang

James B Hoffman

Jason Anthony Rossi

Modesto J Remuiñan Blanco

Araceli Mallo-Rubio

Matthew James Wolfendale

Lluis Ballell

Ilaria Giordano

Modesto J Remuinan Blanco

The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

Antituberculosis agent

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR; or X is C and Y is S; Z is selected from N and CH; Ris selected from H and Calkyl; Ris selected from H, Calkyl, OH, &#x2014;CHOH and Calkoxy; Each Ris independently selected from OH, Calkyl, F, Cl, Br, NH, and Calkoxy; Ris selected from Calkyl and haloCalkyl; Ris selected from H, Calkyl and haloCalkyl; Rand Rare either i) each independently selected from H, Calkyl and Calkoxy; or ii) Rand Rtogether with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and Ris selected from H and Calkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

3-amino-pyrazole derivatives useful against tuberculosis

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR; or X is C and Y is S; Z is selected from N and CH; Ris selected from H and Calkyl; Ris selected from H, Calkyl, OH, &#x2014;CHOH and Calkoxy; Each Ris independently selected from OH, Calkyl, F, Cl, Br, NH, and Calkoxy; Ris selected from Calkyl and haloCalkyl; Ris selected from H, Calkyl and haloCalkyl; Rand Rare either i) each independently selected from H, Calkyl and Calkoxy; or ii) Rand Rtogether with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and Ris selected from H and Calkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

A compound of Formula (I) wherein: either X is N and Y is CRor X is C and Y is S; Z is selected from N and CH; Ris selected from H and Me; Ris selected from H, OH, OMe and Me; each Ris independently selected from Calkyl, F, Cl, Br, CFand NH; Ris selected from Me, CF, NOand CHF; Ris selected from H, Me and CHF; Ris selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

(Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds

Bicyclic nitrogen containing compounds and their use as antibacterials.

Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones

Growing community of inventors

Madrid, Spain

Julia Castro Pichel